Aviezer David 4
4 · Protalix BioTherapeutics, Inc. · Filed May 12, 2009
Insider Transaction Report
Form 4
Aviezer David
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2009-05-12−103,571→ 573,757 totalExercise: $0.12Exp: 2013-12-08→ Common Stock (103,571 underlying) - Sale
Common Stock
2009-05-08$3.40/sh−5,200$17,680→ 0 total(indirect: By Trust) - Sale
Common Stock
2009-05-11$3.41/sh−38,900$132,649→ 0 total(indirect: By Trust) - Sale
Common Stock
2009-05-12$3.41/sh−55,900$190,619→ 0 total(indirect: By Trust) - Exercise/Conversion
Common Stock
2009-05-12$0.12/sh+103,571$12,429→ 0 total(indirect: By Trust) - Tax Payment
Common Stock
2009-05-12$3.48/sh−3,571$12,427→ 0 total(indirect: By Trust)
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The reporting person acquired 100,000 shares of common stock upon the exercise of outstanding options, all of which shares were sold by the reporting person.
- [F3]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- [F4]All of the options listed in Table II have vested.
- [F5]Does not include options to purchase 977,296 shares of common stock at an exercise price equal to $0.972 per share that expire on September 10, 2016, options to purchase 600,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018, and options to purchase 100,000 shares of common stock at an exercise price equal to $2.65 that expire on February 25, 2019.